Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
